JOIN US!

www.sohoitaly.it

15  16  17 March 2021

Virtual Event

20 CME (ECM) HEMATOLOGISTS, ONCOLOGISTS, PATHOLOGIST, BIOLOGISTS
Presidents:
Cerchione C, Martinelli G, Kantarjian H

Scientific Board:

Scientific Secretariat:

Big Faculty:

Young Faculty
Day 0  
15 march 2021

18.15 - 18.30 Welcome and Presentation of the School of Acute Leukemia SOHO Italy Presidents: C. Cerchione, G. Martinelli, H. Kantarjian

18.30 - 19.00 Lecture: How I manage Acute Lymphoblastic Leukemia in USA - H. Kantarjian

19.00 - 19.30 Lecture: How I manage Acute Myeloid Leukemia in Europe - G. Martinelli

19.30 - 20.00 Lecture: How I manage Acute Lymphoblastic Leukemia in USA - H. Kantarjian

20.00 - 20.30 Lecture: How I manage Acute Lymphoblastic Leukemia in Europe - G. Martinelli

20.30 - 21.00 Lecture: How I manage pediatric Acute Leukemias - F. Locatelli

Day 1  
16 March 2021

Frontal Big Faculty Session

08.30 - 08.50 Opening and introduction to the project: C. Cerchione - G. Martinelli

Acute Lymphoblastic Leukemia Biology and MRD Session in ALL: C. Papayannidis, A. Ferrari, C. Quintarelli

08.50 - 09.10 Impact of new opportunities in ALL biology - C. Quintarelli
09.10 - 09.30  Importance of MRD in ALL - C. Papayannidis
09.30 - 09.50  Adut Triple Negative B-ALL fusion landscape: new basis for potential treatments - A. Ferrari
09.50 - 10.00  break

**Biology Session AML - I. Iacobucci, F. Buccisano, G. Rosti**

10.00 - 10.20  New insights into AML Biology - I. Iacobucci
10.20 - 10.40  Molecular Pathogenesis of AML - S. Galimberti
10.40 - 11.00  Importance of MRD assessment and impact on treatment - F. Buccisano

**Clinical Session ALL 1 – G. Martinelli, F. Locatelli, F. Lanza, R. Foà**

11.00 - 11.20  How we manage ALL in daily practice in Europe - G. Martinelli
11.20 - 11.40  Role of monoclonal antibodies in relapsed/refractory ALL - F. Lanza
11.40 - 12.00  Near future of ALL - R. Foà
12.00 - 12.20  CAR Cytokine Induced Killer (CIK) Cells for Relapsed B-Cell Acute Lymphoblastic Leukemia - A. Rambaldi
12.20 - 12.50  Discussion
12.50 - 14.10  Lunch Break
Clinical Session ALL 2 - H. Kantarjian, E. Jabbour, M. Konopleva, A. De La Fuente

14.10 - 14.30 Immunotherapy in adult and elderly ALL - E. Jabbour
14.30 - 14.50 How I manage Ph-positive ALL - E. Jabbour
14.50 - 15.10 How I manage Early T-cell precursors ALL and Ph-like ALL - M. Konopleva
15.10 - 15.30 CAR-T Clinical Trials in ALL - F. Locatelli
15.30 - 15.50 Near future of CAR-T based approach in ALL - J. Ribera

Acute Myeloid Leukemia
Clinical Session AML 1 - C. Cerchione, N. Daver, F. Ravandi

15.50 - 16.10 How we manage AML in daily practice in Europe - G. Martinelli
16.10 - 16.30 How we integrate immunotherapy and target-therapies in AML management - N. Daver
16.30 - 16.50 Optimizing FLT3 inhibitor use in AML in 2021 - N. Daver
16.50 - 17.10 Novel antibodies in AML: new target therapies are possible - F. Ravandi
17.10 - 17.30 Role of IDH inhibitors in AML - M.P. Martelli
17.30 - 17.50 Environment mediated drug resistance in AML - C. Cerchione
17.50 - 18.00 Break
Clinical Session AML 1 - A. Isidori, M. Gottardi, A. Olivieri, A. Lucchesi
18.00-18.20 Elderly AML: present and future - A. Isidori
18.20-18.40 How we manage BDPCN as new entity - L. Pagano
18.40-19.00 Role of allogenic transplant in AML - A. Olivieri
19.00-19.20 Role of maintenance in AML - M. Gottardi

Near future of Acute Leukemias - C. Cerchione, G. Martinelli, H. Kantarjian
19.40-19.50 Take Home Messages and Conclusions of Day 1 - C. Cerchione, G. Martinelli

Day 2 17 March 2021

Young session

Selected oral presentations with project presentations in different categories

1st Session: Biology of Acute Leukemias

09.00 - 09.30 Intracellular and biofluid metabolomics distinguishes two subgroups pf NPM1-mutant Acute Myeloid Leukemia with diverse genomic and transcriptomic signatures G. Simonetti (Meldola, FC)

09.30 - 10.00 MTORC inhibitor decrease G6PD levels and triggers cell death in T-Lymphoblastic Leukemia T-ALL) cells M. Silic-Benussi (Padova)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>Pharmacological inhibition of WIP1 sensitizes Acute Myeloid Leukemia Cells to the MDM2 inhibitor Nutlin-3A - MC. Fontana (Meldola, FC)</td>
</tr>
<tr>
<td>10.30</td>
<td>Understanding the role of the ATR-CHK1 pathway in the response to Doxorubicin-induced DNA damages in Acute Lymphoblastic Leukemia A. Ghelli Luserna Di Rorà (Meldola, FC)</td>
</tr>
<tr>
<td>11.00</td>
<td>Exploring PVT1/CIRCPVT1 roles and their regulation through bromodomain and extra-terminal motif protein inhibitors in Acute Myeloid Leukemia M. Ghetti (Meldola, FC)</td>
</tr>
<tr>
<td>11.30</td>
<td>PALB2 copy number loss associates with poor prognosis AML and suggests novel therapeutics strategies targeting the DNA repair pathway A. Padella (Meldola, FC)</td>
</tr>
<tr>
<td>12.00</td>
<td>Epigenetic regulation of Acute Lymphoblastic Leukemia F. Boccalatte (New York, USA)</td>
</tr>
<tr>
<td>12.30</td>
<td>Open Discussion: Questions and answers and discussion for future papers</td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch Break</td>
</tr>
</tbody>
</table>
3rd Session: Clinical of Acute Leukemias

14.00 - 14.30 Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with AML and MDS: a 15-year monocentric experience - S. Piemontese (Milano)

14.30 - 15.00 Good Risk AML, a heterogeneous group: analysis of outcome according to molecular subgroups A. Fiorentini (Ancona)

15.00 - 15.30 Production of anti CD19 CAR-T cells and rational design of a trial testing anti CD19 CAR-T cell effectioveness in adult with CD19 positive Acute Lymphoblastic Leukemia in complete remission with measurable residual disease G. Marconi (Meldola, FC)

15.30 - 16.00 Development of a novel pharmacological strategy to overcome resistance to ABT-199 in Acute Myeloid Leukemia - V. Raimondi (Padova)


16.30 - 17.00 Oncorelief: a digital guardian angel enhancing cancer patient’s wellbeing and health status improvement following treatment E. Imbrogno (Meldola, FC)
17.00 - 17.30  Baseline CD22 mean fluorescent intensity and Inotuzumab ozogamic for relapsed/refractory B-CELL Acute Lymphoblastic Leukemia
C. Sartor (Bologna)

17.30 - 18.00  Personalized survival prediction of patients with Acute Myeloblastic Leukemia using gene expression profiling
A. Mosquera (Santiago de Compostela, Spain)

18.00 - 18.30  Questions and answers and discussion for future papers

18.30 - 18.45  Conclusion and next steps
in association with

promoted by

supported by an unrestricted educational grant from

astellas

Incyte
Follow us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is #SOHOitLEUKEMIA

You can use it on Facebook, Twitter, Instagram and LinkedIn

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly
@SOHOitLEUKEMIA
@SocietyofHemOnc
@IRSTufficiale
@MDAndersonNews
@pro_eventi
@GMartinelli2
@DottorClaudio

#SOHOitLEUKEMIA